News
-
-
PRESS RELEASE
EQS-Adhoc: Viromed Medical AG expects dynamic growth and announces forecast for 2025 and 2026
Viromed Medical AG expects dynamic growth with revenue forecasted to reach around EUR 8-10 million in 2025 and around EUR 80 million in 2026. The EBIT margin is expected to be in the double-digit range from 2026 onwards -
-
PRESS RELEASE
Viromed Medical AG: Cold plasma technology shows potential to significantly reduce deaths in ventilated patients
Viromed Medical AG's cold plasma technology shows potential to significantly reduce deaths in ventilated patients according to preclinical study, addressing a critical issue in intensive care medicine -
-
-
-
PRESS RELEASE
Viromed Medical AG: Revolutionary cold plasma therapy for the treatment of ventilator-associated pneumonia (VAP) shows 100% efficacy in an in vitro study with MRSA and human lung cells (alveoli)
Viromed Medical AG announces groundbreaking results with cold plasma therapy for ventilator-associated pneumonia (VAP) in an in vitro study. Findings show 100% efficacy against MRSA bacteria without lung cell damage -
-
PRESS RELEASE
Exclusive contract for ViroCAP® My Plasma with Landsberg First Class Aesthetic opens up Viromed's entry into the European cosmetics market
Viromed Medical AG partners with Landsberg First Class Aesthetic to introduce ViroCAP® My Plasma into the European cosmetics market, enhancing aesthetic treatments with cold plasma technology
